Business Context and Reporting Period
Company: Corbus Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date: June 13, 2018
Event: Announcement of data presentation from open-label extensions (OLEs) of Phase 2 clinical studies for lenabasum in systemic sclerosis (SSc) and dermatomyositis (DM) at the Annual European Congress of Rheumatology.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial data and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
Systemic Sclerosis (SSc) Study
- Design: 36 subjects with diffuse cutaneous SSc received lenabasum (20 mg twice daily) following a 16-week double-blind phase. 27 subjects completed 1-year follow-up.
- Efficacy: Modified Rodnan Skin Score (mRSS) improved by a mean of -9.4 points from baseline (baseline: 24 points). 77% of subjects achieved a medically meaningful improvement (reduction ≥ 5 points), and 50% achieved ≥ 10 points improvement.
- Composite Score: ACR CRISS score reached a median of 92%, with 50% of subjects achieving > 95% at 1 year.
- Safety: No severe or serious adverse events (AEs) related to the drug. 92% of subjects experienced AEs; 19% were related to lenabasum. Common AEs included upper respiratory tract infection (22%) and arthralgia (13.9%).
Dermatomyositis (DM) Study
- Design: 20 subjects with refractory, skin-predominant DM received lenabasum (20 mg twice daily). 17 subjects completed 6-month follow-up.
- Efficacy: CDASI activity score improved by a mean of -15.4 points from baseline (baseline: 35 points). 88% achieved reduction ≥ 5 points; 82% achieved reduction ≥ 10 points; 47% achieved a low activity score (≤ 14 points).
- Safety: No severe or serious AEs related to the drug. 65% of subjects experienced AEs; 25% were related to lenabasum. A DM flare occurred in 2 subjects.
Guidance, Outlook, and Risks
- Regulatory Status: Lenabasum has received Orphan Drug Designation and Fast Track status from the FDA for SSc, and Orphan Designation from the EMA.
- Future Trials: The drug is currently being evaluated in the Phase 3 RESOLVE-1 study for diffuse cutaneous SSc.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties related to product development, clinical timelines, and regulatory approvals. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the enrollment and completion rates of the ongoing Phase 3 RESOLVE-1 study.
- Confirm the specific regulatory milestones and expected timelines for the FDA and EMA based on the Phase 2 OLE data.
- Review the full safety profile in the larger Phase 3 population to ensure the absence of severe AEs observed in the Phase 2 OLE.
- Assess the company's cash runway and capital requirements to support the Phase 3 trial completion, as this filing contains no financial data.